Product Description
ALLO-182 together with ALLO-213, an allogeneic CAR T targeting DLL3, represent the company's early-stage solid tumor product candidates. (Sourced from: https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-presents-preclinical-data-novel-allogeneic)
Mechanisms of Action: CAR-T, DLL3
Novel Mechanism: Yes
Modality: Allogeneic CAR-T
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Allogene Therapeutics
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: David Chang
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Small Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/25/2023 |
News Article |
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer |